This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The 5 Dumbest Things on Wall Street This Week: June 7

Stocks in this article: SMG SNTA GOOG CLWR AVEO

Synta's Sorrow

Look 5 Dumbest fans, we're not kidding when we say we want Synta (SNTA) to succeed. Seriously, we take no joy in flagging the foibles of a company dedicated to combatting lung cancer, even if its principal drug does have an utterly unpronounceable name.

That said, it is our sworn duty to shine the spotlight on corporate shortcomings wherever they may reside, whether it be cupcake or cancer companies. And that's why we cannot ignore the mistakes that led to a 34% shellacking in Synta's shares Monday.

Sorry Synta, but that's what happens when you put the ganetespib before the horse!

To put it as simply as possible, a Phase II trial result revealed at the ASCO Conference on Monday did show that ganetespib improved survival in patients with advanced lung cancer. Nevertheless, the difference in patient deaths was relatively small and certainly not statistically significant enough to impress anybody, especially Synta investors who promptly took the stock to the woodshed.

Even before those lackluster results were publicly revealed, however, Synta was already pushing patients to enroll in a phase III study of ganetespib in second-line lung cancer. As to why they think skipping ahead to the next level without truly clearing the previous bar will get them closer to an FDA approval for their drug, well, we have no clue, and already-skeptical investors clearly feel the same way.

"If there was any enthusiasm for ganetespib going into the ASCO meeting, it's likely taking a hit now that investors have fixated on the anti-PD-1 drugs from Bristol-Myers Squibb (BMY) and Merck (MRK), says TheStreet's biotech ax Adam Feuerstein. "Unlike Synta's offering, these drugs are producing some of the strongest responses to melanoma ever seen and are also targeting lung cancer."

Sad to say, but Synta seems to be heading in the wrong direction.

Even worse, they feel the need to sprint.

2 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs